Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 1/20 | 0.42 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.42 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR2B | P41595 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3789653 | 0.95 | TP53 (0.53) | TP53RECQLOPRL1ADRA1ADPP4 | |
| SCHEMBL2316090 | 0.93 | TP53 (0.52) | TP53RECQLOPRL1ADRA1ADPP4 | |
| SCHEMBL1897406 | 0.90 | TP53 (0.57) | TP53RECQLOPRL1ADRA1ADPP4 | |
| Charcoal, Activated SCHEMBL5897477 | 0.88 | TP53 (0.55) | TP53RECQLOPRL1ADRA1ADPP4 | |
| Acetonitrile SCHEMBL28780186 | 0.82 | TP53 (0.43) | TP53RECQLOPRL1ADRA1AADRA1B | |
| SCHEMBL4065015 | 0.82 | TP53 (0.50) | TP53RECQLOPRL1ADRA1ADPP4 | |
| SCHEMBL6568327 | 0.81 | DPP4 (0.52) | TP53RECQLOPRL1DPP4HTR2A | |
| SCHEMBL6567731 | 0.81 | DPP4 (0.52) | TP53RECQLOPRL1DPP4HTR2A | |
| SCHEMBL6568329 | 0.81 | DPP4 (0.52) | TP53RECQLOPRL1DPP4HTR2A | |
| SCHEMBL6567736 | 0.81 | DPP4 (0.52) | TP53RECQLOPRL1DPP4HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2017-03-02 | — | — | US | disclosed |
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | SUMITOMO CHEMICAL COMPANY LIMITED (JP) | 2010-04-08 | — | — | US | disclosed |
| EP-1914221-A1 | PROCESS FOR PRODUCING BIARYL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2008-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100087680-A1 | METHOD FOR PRODUCING BIARYL COMPOUND | NISCH, BLVRB, BBOX1 | TP53 2819/4885RECQL 1576/4885OPRL1 3833/4885 |
| US-20170057983-A1 | Phosphonate Compounds for Treatment of Medical Disorders | CFD, TFPI, CFH | TP53 3421/4885RECQL 396/4885OPRL1 3156/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.